dc.contributor.author | Nosrati, H | |
dc.contributor.author | Abbasi, R | |
dc.contributor.author | Charmi, J | |
dc.contributor.author | Rakhshbahar, A | |
dc.contributor.author | Aliakbarzadeh, F | |
dc.contributor.author | Danafar, H | |
dc.contributor.author | Davaran, S | |
dc.date.accessioned | 2018-08-26T08:55:38Z | |
dc.date.available | 2018-08-26T08:55:38Z | |
dc.date.issued | 2018 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54331 | |
dc.description.abstract | This work described a folic acid conjugated delivery of chrysin-loaded bovine serum albumin nanoparticles, which could overcome the nonspecific targeting disadvantage. Chrysin (5, 7-dihydroxyflavone) is a natural flavonoid which have some significant biological effects on the processes of chemical defense. Chrysin loaded bovine serum albumin nanoparticles (Chrysin-BSA NPs) were synthesized by a simple desolvation procedure. Afterward, folic acid (FA) was conjugated to the surface of Chrysin-BSA NPs by carbodiimide chemistry (Chrysin-BSA-FA NPs). The resultant Chrysin-BSA-FA NPs showed a spherical shape, with a hydrodynamic diameter of 97.5 آ± 5.8 nm (mean آ± SD) nm and a ?-potential of ?11.3 mV. The in vitro drug release study of chrysin presented a sustained and controlled release pattern. Hemolysis assay and cytotoxicity study results on HFF-2 cell line show that as prepared BSA NPs are biocompatible. Both the Chrysin-BSA NPs and Chrysin-BSA-FA NPs prompted an enhanced cancer cell cytotoxic effect in contrast to chrysin solution. These data recommended that the folate-modified chrysin -loaded vehicle, which demonstrated better biocompatibility and potential superiority, could be a suitable cancer therapy in targeting tumors in the future. é 2018 Elsevier B.V. | |
dc.language.iso | English | |
dc.relation.ispartof | International Journal of Biological Macromolecules | |
dc.subject | bovine serum albumin | |
dc.subject | chrysin | |
dc.subject | folate receptor | |
dc.subject | folic acid | |
dc.subject | nanoparticle | |
dc.subject | antineoplastic activity | |
dc.subject | Article | |
dc.subject | biocompatibility | |
dc.subject | breast cancer | |
dc.subject | cancer cell | |
dc.subject | controlled study | |
dc.subject | cytotoxicity assay | |
dc.subject | drug conjugation | |
dc.subject | drug cytotoxicity | |
dc.subject | drug delivery system | |
dc.subject | drug formulation | |
dc.subject | hemolysis assay | |
dc.subject | human | |
dc.subject | human cell | |
dc.subject | hydrodynamics | |
dc.subject | in vitro study | |
dc.subject | MCF-7 cell line | |
dc.subject | nanoencapsulation | |
dc.subject | particle size | |
dc.subject | sustained drug release | |
dc.subject | zeta potential | |
dc.title | Folic acid conjugated bovine serum albumin: An efficient smart and tumor targeted biomacromolecule for inhibition folate receptor positive cancer cells | |
dc.type | Article | |
dc.citation.volume | 117 | |
dc.citation.spage | 1125 | |
dc.citation.epage | 1132 | |
dc.citation.index | Scopus | |
dc.identifier.DOI | https://doi.org/10.1016/j.ijbiomac.2018.06.026 | |